Shuchi Gulati — AKCI

Dr. Shuchi Gulati, MD FACP

Claim this profile

University of Cincinnati Medical Center

Studies Cancer
Studies Parotid Gland Cancer
13 reported clinical trials
26 drugs studied

Area of expertise

1Cancer
Shuchi Gulati, MD FACP has run 7 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
ARID1A positive
2Parotid Gland Cancer
Shuchi Gulati, MD FACP has run 6 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
ARID1A positive
Stage III

Affiliated Hospitals

Image of trial facility.
University Of Cincinnati Medical Center
Image of trial facility.
University Of Cincinnati Cancer Center-UC Medical Center

Clinical Trials Shuchi Gulati, MD FACP is currently running

Image of trial facility.

Cabozantinib +/− Atezolizumab

for Advanced Kidney Cancer

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
Image of trial facility.

Radium-223 + Docetaxel

for Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria

More about Shuchi Gulati, MD FACP

Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Shuchi Gulati, MD FACP has experience with
  • Pembrolizumab
  • Nivolumab
  • Ipilimumab
  • ONC-392
  • Biospecimen Collection
  • Cabozantinib S-malate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Shuchi Gulati, MD FACP specialize in?
Is Shuchi Gulati, MD FACP currently recruiting for clinical trials?
Are there any treatments that Shuchi Gulati, MD FACP has studied deeply?
What is the best way to schedule an appointment with Shuchi Gulati, MD FACP?
What is the office address of Shuchi Gulati, MD FACP?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security